Division of Plastic and Reconstructive Surgery, Children's National Hospital, Washington, DC.
J Craniofac Surg. 2022;33(2):543-547. doi: 10.1097/SCS.0000000000008353.
Suboptimal pain management after primary palatoplasty (PP) may lead to complications such as hypoxemia, and increased hospital length of stay. Opioids are the first option for postoperative acute pain control after PP; however, adverse effects include excessive sedation, respiratory depression, and death, among others. Thus, optimizing postoperative pain control using opioid-sparing techniques is critically important. This paper aims to analyze efficacy and safety of combined intravenous (IV), dexmedetomidine, and IV acetaminophen during PP.
Review of a cohort of patients who underwent PP from April 2009 to July 2018 at a large free-standing children's hospital was performed, comparing patients who received combined IV dexmedetomidine and acetaminophen with those who did not receive either of the 2 medications. Efficacy was measured through opioid and nonopioid analgesic dose and timing, pain scores, duration to oral intake, and length of stay. Safety was measured by 30-day complication rates including readmission for bleeding and need for supplementary oxygen.
Total postoperative acetaminophen (P = 0.01) and recovery room fentanyl (P < 0.001) requirements were significantly lower in the study group compared with the control group. Length of stay, oral intake duration, pain scores, total postoperative opioid requirements, and complications rates trended favorably in the study group, though differences did not reach statistical significance.
Intraoperative IV dexmedetomidine and acetaminophen during PP provides safe and effective perioperative pain control, resulting in statistically significant decreased need for postoperative acetaminophen and fentanyl. Larger studies are necessary to determine if other trends identified in this study may be significant.
初次腭裂修复术(PP)后疼痛管理不充分可能导致低氧血症和住院时间延长等并发症。阿片类药物是 PP 后急性疼痛控制的首选药物;然而,其不良反应包括过度镇静、呼吸抑制和死亡等。因此,使用阿片类药物节约技术优化术后疼痛控制至关重要。本文旨在分析 PP 期间联合使用静脉内(IV)右美托咪定、地塞米松和 IV 对乙酰氨基酚的疗效和安全性。
回顾 2009 年 4 月至 2018 年 7 月在一家大型独立儿童医院接受 PP 的患者队列,比较接受 IV 右美托咪定和对乙酰氨基酚联合治疗与未接受这两种药物治疗的患者。通过阿片类药物和非阿片类药物的剂量和时间、疼痛评分、开始口服摄入的时间和住院时间来衡量疗效。通过 30 天的并发症发生率(包括因出血再次入院和需要补充氧气)来衡量安全性。
与对照组相比,研究组术后总对乙酰氨基酚(P=0.01)和恢复室芬太尼(P<0.001)的需求明显降低。尽管研究组在住院时间、口服摄入时间、疼痛评分、术后总阿片类药物需求和并发症发生率方面有良好的趋势,但差异没有达到统计学意义。
PP 期间静脉内 IV 右美托咪定和对乙酰氨基酚可提供安全有效的围手术期疼痛控制,可显著减少术后对乙酰氨基酚和芬太尼的需求。需要更大的研究来确定本研究中确定的其他趋势是否具有重要意义。